Submission Deadline: 31 December 2023 (Status: Open)
Special Issue Editors
Dr. Jitendra Kumar Sinha Email | Website
GloNeuro Academy, Noida, India
Interests: neurotherapeutics; neurodegenerative disorders; neurobiology of obesity; sleep; epilepsy; spinal cord in-jury; sleep technology; digital health; democratizing health for all
Dr. Shampa Ghosh Email | Website
GloNeuro Academy, Noida, India
Interests: amyotrophic lateral sclerosis; neurotherapeutics; developmental origins of health and disease (dohad); vitamin b12; sleep; spinal cord injury; epilepsy; digital health; maternal and child health; nutrition
Special Issue Information
Neurological, neuropsychological, and neuropsychiatric disorders are a heavy burden on the overall health of a nation. They not only impact the physical and mental health of individuals but also the sus-tainability of families, communities, and the nation as a whole. The economic burden is high when there is a lack of early diagnosis, and the treatment is missed. Additionally, the lack of biological markers for many Central Nervous System (CNS) disorders and their stages of progression, impacts diminish the ability to di-agnose and treat these disorders. Moreover, the genetic makeup, epigenomic differences and environ-mental factors, including the exposure to different substances and nutritional status substantially changes the course of treatment of CNS disorders.
Therefore, it is very important to improve the quality of available drugs and therapies to treat and manage these disorders effectively. Alongside this, it becomes important to discuss and update with the commu-nity of scientists and physicians the latest developments in drug discovery, target identification - valida-tion, preclinical, and clinical development of therapies that are beneficial for CNS disorders. The knowledge of drug action at both cellular and molecular levels would help to unveil the role of certain molecules and compounds in CNS disorders. There is a critical need to discuss recent advances in cellular and molecular pharmacology, the mechanism of action of novel drugs, cell signalling, genomics, prote-omics, and metabolomics.
The aim of this special issue is to publish a comprehensive set of articles under the title “Molecular Neu-ropharmacology: Drugs and Therapeutics”. Submissions in any of the following categories will be consid-ered: Original Research articles, Reviews, and Mini-Reviews. This special issue will focus (but not limited to) on the current and novel intervention methods involve in the treatment of neurological and neuropsy-chological disorders and future directions of current therapies.
Jitendra Kumar Sinha and Shampa Ghosh
seizures; therapeutics; paediatric and adult types; EEG; TMS; non-invasive brain stimulation; epilepsy sur-gery; ethnopharmacology; cognition; depression
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://www.biolifesas.org/journalx_brha/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.